Revolutionizing Medicines and Materials Discovery 1Q25 Financial Results May 7, 2025 Cautionary Note and Disclaimer This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, made by Schrödinger, Inc. ("we," "us," "our," "Schrödinger," or the "Company") contained in this presentation, including, without limitation, st ...

Marqeta Earnings Supplement May 7, 2025 1 Safe Harbor Statement This earnings supplement contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this presentation include, but are not limited to, statements relating to Marqeta's quarterly and annual guidance; statements regarding Marqeta's business plans, business strategy and the continued success and growth of our cu ...

MAY 2025 Investor Presentation Forward-looking statements disclaimer This presentation contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward- looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts contained in this presentation may be forward-looking statements. In some cases, you can identify forw ...

CSG Q1 2025 Earnings Presentation Brian Shepherd CEO & President Hai Tran CFO Safe Harbor Forward-Looking Statements + Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," ...

Financial Performance - Total Q1 revenue reached $244.3 million, a 19% increase year-over-year[10, 44] - NUPLAZID sales in Q1 were $159.7 million, up 23% year-over-year, marking the highest ever quarterly sales[11, 23, 44] - DAYBUE sales in Q1 were $84.6 million, an 11% increase compared to Q1 2024[11, 17, 44] - Net income for Q1 was $19.0 million, a 14% increase year-over-year[44] - Earnings per share (EPS) for Q1 was $0.11, a 10% increase year-over-year[44] Product Updates - DAYBUE saw 954 unique patients receiving the therapy in Q1[18] - DAYBUE discontinuations decreased by 35% compared to Q4 2024 and 66% compared to Q1 2024[18] - 65% of active DAYBUE patients have been on therapy for 12 months or longer, with persistency rates above 50% at 12 months[18] Research and Development - Topline results from the COMPASS PWS Phase 3 trial with ACP-101 are now expected in early Q4 2025[12, 29] - The last patient-in for the COMPASS PWS Phase 3 trial is now expected in Q2 2025[29] - A Phase 2 study of ACP-204 in Lewy Body Dementia Psychosis (LBDP) is on track to initiate in Q3 2025[37] - Last patient-in for the Phase 2 study of ACP-204 in Alzheimer's Disease Psychosis (ADP) is expected in Q1 2026, with topline results expected mid-2026[38] Financial Guidance - The company anticipates total revenue between $1.03 billion and $1.095 billion for FY 2025[45] - NUPLAZID net sales are projected to be between $650 million and $690 million for FY 2025[45] - DAYBUE net sales are projected to be between $380 million and $405 million for FY 2025[45] - R&D expense is expected to be between $330 million and $350 million for FY 2025[45] - SG&A expense is expected to be between $535 million and $565 million for FY 2025[45]

1Q25 Earnings Presentation May 7, 2025 Published by: Sinclair, Inc. 111 NON-GAAP FINANCIAL MEASURES This presentation contains certain financial measures of Sinclair, Inc. (the "Company"), including Adjusted EBITDA, which are not prepared in accordance with U.S. generally accepted accounting principles ("GAAP") (collectively, the "non-GAAP financial measures"). Adjusted EBITDA is defined as earnings before interest, tax, depreciation and amortization, and non-recurring and unusual transaction, implementatio ...

Financial Performance & Market Opportunity - IonQ预计2025财年收入为7500万美元至9500万美元[13] - 截至2025年3月31日，IonQ的现金、现金等价物和投资为6.971亿美元[13] - 到2035年，量子计算、安全和网络市场的潜在市场规模（TAM）预计将达到870亿美元[13] - 量子计算和网络预计到2040年将创造高达8800亿美元的经济价值[18] Technology & Innovation - IonQ拥有超过950项量子计算和量子网络专利组合（包括已授权和待批准的专利）[12, 21, 23] - IonQ正在开发通往数百万量子比特的路径，这得益于对Lightsynq的拟议收购[8] - IonQ的离子阱架构具有高保真度和连接性，以及较低的纠错开销[8, 39] Commercialization & Partnerships - IonQ是唯一在所有主要云平台上提供量子硬件的公司[13] - IonQ正在通过与EPB的2200万美元交易，开发量子就绪型劳动力[70] - IonQ正在扩展其亚太地区的生态系统，并在日本和韩国签署了谅解备忘录（MOU）[62] Strategic Expansion - IonQ正在通过收购和合作，扩大其全球业务范围，包括收购Qubitekk、Entangled Networks以及ID Quantique的多数股权[61] - IonQ正在开发量子中继器，以扩展量子网络的范围，目标是在中继器之间实现数百公里的距离[88, 90]

Business Transformation & Strategy - Core Scientific is transitioning from bitcoin mining to a high-density colocation provider[11] - The company aims to build a 1.3 GW+ billable power capacity data center platform by 2027[15] - Diversifying customer base and expanding colocation capacity through organic growth and M&A are key catalysts for 2025[42] Colocation Contracts & Revenue - Core Scientific has signed colocation contracts with potential revenue exceeding $10 Billion over 12 years[7, 12] - CoreWeave contracts contribute to approximately $850 Million in average annual run rate revenue[22] - The company anticipates a 75% to 80% profit margin from CoreWeave colocation contracts[22] Financial Performance & Debt - Q1 2025 colocation revenue was $8.573 Million, a 100% increase compared to Q1 2024[55] - Total debt as of March 31, 2025, was $1.119 Billion[46] - The company reported a net income of $580.693 Million for the three months ended March 31, 2025[55]

Forward Air Corporation Earnings Presentation 1Q25 May 7, 2025 Earnings Presentation Statements & Disclaimers Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "wil ...

This presentation will reference certain non-GAAP financial information. For a description and reconciliation of non-GAAP measures presented in this document, please see the appendix attached to this presentation or visit the Investor Relations section of the Evertec website at www.evertecinc.com. Business Summary Mac Schuessler, President and CEO First Quarter Earnings Conference call May 7, 2025 Foward looking statements Certain statements in this presentation constitute "forward-looking statements" withi ...